Peptides studied for cognitive function — ranked by Russian and Western human research.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Most nootropic peptide research originated in Russian institutional research and has not been broadly replicated in Western clinical trials. This guide summarizes what has been published and where the gaps are.
How we ranked: Ordered by: (1) Western replication, (2) Russian clinical data volume, (3) mechanism, (4) safety in human exposure.
ACTH(4-10)-derived heptapeptide developed for stroke and cognitive enhancement. Registered as a medication in Russia. Western trials are minimal but intranasal mechanism and BDNF upregulation are plausible.
Tuftsin-based anxiolytic heptapeptide. Russian clinical data for generalized anxiety; mechanism involves GABAergic modulation. Not FDA approved; not well studied in Western populations.
Not a peptide but widely used in this space. Supplementation raises cellular NAD+ pool, involved in neuronal energy metabolism. Human cognitive outcomes are not robustly established.
Neither is FDA approved. They are available as research chemicals only and are not legal for human consumption in the United States.
Russian clinical literature on semax and selank reports cognitive and anxiolytic benefits. The data has not been extensively replicated in Western trials, so confidence in these effects is moderate at best.
No peptide nootropic has a safety profile established through extensive Western pharmacovigilance. Claims of "safety" typically reference limited Russian trial data.